NCT02268851 2024-11-15A Phase I/Ib Safety and Efficacy Study of the PI3K-delta Inhibitor TGR-1202 and Ibrutinib in Patients With CLL or MCLDana-Farber Cancer InstitutePhase 1 Completed45 enrolled 13 charts
NCT04692155 2023-09-28CHOP U2University of Alabama at BirminghamPhase 1/2 Terminated1 enrolled 5 charts